DrugEvidence

Diseases / Myocardial Infarction

Myocardial Infarction

Disease

Myocardial infarction (heart attack) occurs when coronary blood flow is severely reduced or blocked, causing ischemic injury and necrosis of heart muscle. It is a major cause of cardiovascular morbidity and mortality.

Trials
1951
Recruiting
178
Completed
1096
With results
183

Last revised

Pipeline

Phase by status

PhaseRecruitingNot yetBy invitationActiveCompletedTerminatedWithdrawnSuspendedUnknownAvailableTemporarily not availableTotal
Early Phase 1 1131 6
Phase 1 1124325 36
Phase 1/2 184310 35
Phase 2 63136212517 109
Phase 2/3 211856 32
Phase 3 1211131154119 184
Phase 4 175412415544 214
Not applicable 612472829728142111 572
Unknown 7828633419201616111 763

Trials started per year

2021
26
2022
87
2023
86
2024
68
2025
72
2026
77
2027
2

Conditions studied, by phase

ConditionEarly Phase 1Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Not applicableUnknownTotal
Myocardial Infarction 6363510932184214572763 1951
Coronary Artery Disease 2831631826116108 300
Cardiovascular Diseases 152111542154136 285
Acute Coronary Syndrome 122121292256111 236
Stroke 13124292542123 230
Myocardial Ischemia 13317335124468 186
Heart Failure 1841131974583 181
Heart Diseases 431023882191 177
ST Elevation Myocardial Infarction 3315320225852 176
Coronary Disease 2192882687 161

Most active sponsors

#SponsorTrialsPhase 3
1National Heart, Lung, and Blood Institute (NHLBI)6420
2University of Edinburgh190
3Mayo Clinic181
4Brigham and Women's Hospital173
5AstraZeneca163
6Karolinska Institutet162
7University College, London160
8Assistance Publique - Hôpitaux de Paris146
9Assiut University130
10Deutsches Herzzentrum Muenchen131

Most studied interventions

#InterventionTrials
1Clopidogrel53
2Aspirin44
3Ticagrelor43
4Percutaneous Coronary Intervention37
5Standard of Care20
6Atorvastatin19
7Abciximab16
8Prasugrel Hydrochloride16
9Blood Specimen Collection15
10Exercise12

Evidence

Results reported
16.7%183 of 1096 completed
Published
21.6%237 of 1096 completed
Primary endpoint met
41.1%60 of 146 analyses
Median months to report
17.5

Documents disclosed

Protocol available
124
Statistical analysis plan
114
PubMed citations
988

Trial profile

Median enrollment
220
Median duration
37.1months
Countries
95
Study sites
16820

Who is enrolled

Adults
1915
Children
188
Older adults
1898
Healthy volunteers
198

Median enrollment by phase

Early Phase 1
105
Phase 1
25
Phase 1/2
27
Phase 2
98
Phase 2/3
106
Phase 3
568
Phase 4
240
Not applicable
131
Unknown
543

Where trials run

United States
404
Canada
163
United Kingdom
155
France
146
Germany
139
China
121
Italy
117
Spain
112
Netherlands
110
Denmark
89

Busiest cities

#CityCountryTrials
1New YorkUnited States76
2BostonUnited States67
3LondonUnited Kingdom67
4BarcelonaSpain63
5ParisFrance60
6TorontoCanada60
7HoustonUnited States59
8RochesterUnited States59
9SeoulSouth Korea58
10MontrealCanada57

Terminations

Terminated
102
Withdrawn
49
Suspended
3
Stopped for recruitment
1.2%23 of 1951 trials

Stated reasons

Other / unclear
84
Recruitment
23
Funding
21
COVID-19
9
Regulatory
9
Lack of efficacy
5
Business decision
2
Safety
1

Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.

Recently stopped

TrialStatusStated reasonStopped
NCT02503280 Withdrawn Withdrawn Study has never enrolled any subjects 2032-03-31
NCT06742684 Withdrawn Withdrawn The study could not be started due to a lack of funding for the provision of the medical product to be investigated. 2029-08-31
NCT05494151 Withdrawn Withdrawn Due to unforeseen challenges in participant recruitment and retention, the study was early terminated to maintain the integrity of the data and ensure ethical standards were upheld. 2026-09-01
NCT04218786 Withdrawn Withdrawn Due to the pandemic, there were logistical issues in continuing the study. 2026-06-30
NCT05720156 Withdrawn Withdrawn Lack of Feasibility 2026-03-31
NCT03729401 Terminated Terminated Testing supplies unavailable. 2026-02-26
NCT07693712 Terminated Terminated Staffing challenges and subsequent withdrawal of funding. 2026-02-26
NCT06139328 Terminated Terminated Sponsor decision 2025-12-02
NCT03289728 Terminated Terminated According interim analysis results 2025-07-28
NCT06280976 Withdrawn Withdrawn study withdrawn, no participants enrolled, changes in the study design planned 2025-01-01

Trial records